Clinical Trials
1
Active:0
Completed:1
Trial Phases
1 Phases
Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (100.0%)Vaccine Enriched, Autologous, Activated T-Cells Directed to Tumor in Patients With Relapsed/Refractory Melanoma
Phase 1
Completed
- Conditions
- Melanoma
- First Posted Date
- 2015-06-26
- Last Posted Date
- 2022-02-04
- Lead Sponsor
- Gary Doolittle
- Target Recruit Count
- 7
- Registration Number
- NCT02482532
- Locations
- 🇺🇸
KU Cancer Center, Fairway, Kansas, United States
News
No news found